Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN60300 in Advanced Solid Tumours
NCT07213817Phase 2Recruiting
- Sponsor
- Ipsen
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of IPN60300 in solid tumor, sponsored by Ipsen. Started Dec 2025; status: recruiting.
02
Drugs
IPN60300
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07213817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213817.